Effect of loratadine on human eosinophil function in vitro.
We investigated the in vitro effect of loratadine, a new nonsedating H1 histamine antagonist, on the eosinophil functions of chemotaxis, superoxide anion (O2-) generation and eosinophil cationic protein (ECP) release, using purified eosinophils obtained from allergic patients. Loratadine significantly attenuated platelet-activating factor (PAF)-induced eosinophil chemotaxis and O2- generation at therapeutic concentrations (equivalent to serum concentrations after single oral administration of 20 mg or 40 mg). Loratadine, however, had no effect on PAF-induced ECP release. These findings suggest that loratadine has a direct inhibitory effect on eosinophil activation and may be beneficial in the therapy of allergic disorders with its anti-allergic properties.
Eda
R
R
Allergic Disease Center, Creighton University School of Medicine, Omaha, Nebraska.
Sugiyama
H
H
Hopp
R J
RJ
Bewtra
A K
AK
Townley
R G
RG
D000284:Administration, Oral; D000328:Adult; D001798:Blood Proteins / Q000378:metabolism; D002469:Cell Separation; D002633:Chemotaxis / Q000187:drug effects / Q000502:physiology; D047091:Eosinophil Granule Proteins; D004804:Eosinophils / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D017336:Loratadine / Q000008:administration & dosage / Q000494:pharmacology*; D008875:Middle Aged; D012260:Ribonucleases; D013481:Superoxides / Q000378:metabolism
D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D013481:Superoxides; D017336:Loratadine; D012260:Ribonucleases